Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
AQST

AQST - Aquestive Therapeutics Inc Stock Price, Fair Value and News

2.48USD-0.17 (-6.42%)Delayed as of 21 Feb 2024, 02:02 pm ET
Watchlist

Market Summary

USD2.48-0.17
Delayedas of 21 Feb 2024, 02:02 pm
-6.42%

AQST Stock Price

View Fullscreen

AQST RSI Chart

AQST Valuation

Market Cap

176.9M

Price/Earnings (Trailing)

-14.61

Price/Sales (Trailing)

3.44

EV/EBITDA

-30.54

Price/Free Cashflow

29.47

AQST Price/Sales (Trailing)

AQST Profitability

EBT Margin

-23.26%

Return on Equity

-5.82%

Return on Assets

-20.37%

Free Cashflow Yield

3.39%

AQST Fundamentals

AQST Revenue

Revenue (TTM)

51.4M

Rev. Growth (Yr)

13.43%

Rev. Growth (Qtr)

-1.81%

AQST Earnings

Earnings (TTM)

-12.1M

Earnings Growth (Yr)

83.77%

Earnings Growth (Qtr)

64.87%

Breaking Down AQST Revenue

52 Week Range

0.722.70
(Low)(High)

Last 7 days

-2.2%

Last 30 days

2.3%

Last 90 days

55.5%

Trailing 12 Months

209.2%

How does AQST drawdown profile look like?

AQST Financial Health

Current Ratio

1.76

AQST Investor Care

Shares Dilution (1Y)

23.29%

Diluted EPS (TTM)

-0.24

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202349.9M49.9M51.4M0
202252.0M49.9M48.1M47.7M
202148.2M41.9M46.9M50.8M
202048.7M59.3M55.1M45.8M
201956.7M53.9M53.0M52.6M
201873.9M76.7M62.8M67.4M
201700066.9M

Tracking the Latest Insider Buys and Sells of Aquestive Therapeutics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Aug 09, 2023
kraus carl n
acquired
-
-
150,000
chief medical officer
Mar 09, 2023
boyd peter e.
acquired
-
-
100,000
see remark
Mar 09, 2023
barber daniel
acquired
-
-
447,000
president and ceo
Mar 09, 2023
schobel alexander mark
acquired
-
-
100,000
chief innovation/tech officer
Mar 09, 2023
braender lori j
acquired
-
-
150,000
svp, general counsel
Mar 09, 2023
jung cassie
acquired
-
-
110,000
svp, operations
Mar 09, 2023
wargacki stephen
acquired
-
-
135,000
svp, research & development
Mar 09, 2023
marshall ken w.
acquired
-
-
150,000
svp, chief commercial officer
Mar 09, 2023
toth a ernest jr
acquired
-
-
140,000
svp, chief financial officer
Jun 14, 2022
boyd peter e.
bought
4,050
0.81
5,000
svp-bus. process & info. tech.

1–10 of 50

Which funds bought or sold AQST recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 16, 2024
GSA CAPITAL PARTNERS LLP
sold off
-100
-154,000
-
-%
Feb 15, 2024
BARCLAYS PLC
sold off
-100
-11,000
-
-%
Feb 15, 2024
JANE STREET GROUP, LLC
new
-
315,292
315,292
-%
Feb 14, 2024
VANGUARD GROUP INC
added
11.21
1,216,950
3,815,890
-%
Feb 14, 2024
CITADEL ADVISORS LLC
added
6,103
334,851
338,990
-%
Feb 14, 2024
STATE STREET CORP
added
10.34
95,979
306,105
-%
Feb 14, 2024
BANK OF AMERICA CORP /DE/
new
-
17,599
17,599
-%
Feb 14, 2024
Coppell Advisory Solutions LLC
reduced
-56.76
-1.00
32.00
-%
Feb 14, 2024
OCCUDO QUANTITATIVE STRATEGIES LP
reduced
-41.05
-20,299
71,239
0.01%

1–10 of 43

Are Funds Buying or Selling AQST?

Are funds buying AQST calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own AQST
No. of Funds

Unveiling Aquestive Therapeutics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
armistice capital, llc
5.88%
3,924,000
SC 13G
Feb 11, 2022
bratton douglas k
8.6%
3,468,747
SC 13G/A
Feb 16, 2021
perceptive advisors llc
4.1%
1,385,720
SC 13G/A
Feb 09, 2021
bratton douglas k
12.0%
13
SC 13G/A
Dec 01, 2020
madryn asset management, lp
4.2%
1,530,717
SC 13G/A
Feb 14, 2020
perceptive advisors llc
7.0%
2,250,000
SC 13G/A
Feb 12, 2020
bratton douglas k
16.1%
13
SC 13G/A
Sep 09, 2019
madryn asset management, lp
5.5%
1,428,572
SC 13G

Recent SEC filings of Aquestive Therapeutics Inc

View All Filings
Date Filed Form Type Document
Feb 14, 2024
SC 13G
Major Ownership Report
Feb 12, 2024
S-8
Employee Benefits Plan
Dec 19, 2023
UPLOAD
UPLOAD
Dec 13, 2023
CORRESP
CORRESP
Dec 08, 2023
8-K
Current Report
Dec 05, 2023
8-K
Current Report

Peers (Alternatives to Aquestive Therapeutics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
380.2B
93.0B
-3.60% -2.76%
10.82
4.09
6.46% 95.94%
155.8B
23.6B
-3.76% -37.06%
-118.38
6.6
-28.02% -113.34%
151.9B
28.2B
-7.44% 18.02%
22.62
5.39
7.09% 2.52%
89.8B
27.4B
-17.13% -16.65%
15.28
3.28
0.94% 76.21%
14.7B
15.8B
15.02% 26.90%
-26.21
0.92
6.17% 77.01%
MID-CAP
5.1B
1.6B
14.11% 18.79%
23.62
3.19
40.56% 266.27%
4.4B
4.7B
-2.94% -9.06%
-1.1K
0.94
5.74% 96.18%
3.1B
8.5B
-0.23% 18.85%
-3.26
0.37
5.11% -479.13%
2.5B
601.3M
-0.28% 70.16%
18.57
4.18
24.02% 75.17%
SMALL-CAP
1.3B
700.5M
2.67% -
-0.93
1.91
16.26% -147.49%
24.0M
70.0M
-0.88% -54.80%
0.35
0.34
-19.54% 888.31%
21.2M
84.1M
58.23% -28.98%
-0.99
0.22
2882.68% -145.15%
17.3M
111.1M
-6.33% -18.68%
-1.08
0.16
-10.43% 84.90%
2.6M
20.0M
-35.83% -91.10%
-0.19
0.13
137.71% 66.04%

Aquestive Therapeutics Inc News

Latest updates
Yahoo Finance20 hours ago
Yahoo Finance03 Jan 202408:00 am

Aquestive Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Revenue-1.8%13,002,00013,241,00014,513,00010,682,00011,463,00013,265,00012,270,00011,078,00013,287,00015,345,00011,122,0007,149,0008,260,00021,675,0008,765,00016,419,00012,418,00011,129,00012,643,00016,824,00013,267,000
Costs and Expenses-11.9%15,379,00017,450,00015,739,000-20,316,00026,027,00022,008,000-21,255,00021,862,00019,647,00022,795,00022,041,00021,280,00022,626,00026,323,00023,420,00029,817,00025,717,000--
Operating Expenses---------------22,626,00026,323,00023,420,00029,817,00025,717,00029,173,00022,471,000
  S&GA Expenses0.3%7,385,0007,360,0007,455,00011,812,00012,459,00015,587,00013,021,00014,981,00012,129,00013,134,00013,231,00015,582,00011,803,00013,894,00014,613,00016,474,00013,714,00016,246,00017,908,00018,698,00012,346,000
  R&D Expenses-8.0%3,196,0003,473,0003,547,0004,278,0003,232,0005,198,0004,773,0004,400,0004,726,0004,262,0003,659,0004,425,0007,260,0003,847,0004,354,0003,057,0005,063,0008,151,0004,303,0005,683,0004,534,000
EBITDA Margin67.0%-0.10-0.29-0.50-0.95-1.28-1.25-1.10-1.13-1.01-1.19-0.82-0.90---------
Interest Expenses-8.5%1,256,0001,373,0001,435,0001,650,0001,649,0001,635,0001,618,0001,744,0002,787,0002,757,0002,761,0002,768,0002,778,0002,747,0002,771,0002,803,0002,652,0001,937,0001,926,0001,913,0001,933,000
Income Taxes-149.3%-140,000284,000-------------------
Earnings Before Taxes60.5%-2,175,000-5,508,0008,068,000-12,352,000-12,536,000-16,302,000-13,220,000-28,945,000-14,555,000-12,367,000-14,672,000-20,368,000-16,551,000-2,334,000-16,530,000-12,636,000-18,412,000-20,472,000-14,726,000-13,944,000-15,038,000
EBT Margin48.0%-0.23-0.45-0.66-1.14-1.48-1.46-1.33-1.39-1.32-1.53-1.12-1.22---------
Net Income64.9%-2,035,000-5,792,0008,068,000-12,352,000-12,536,000-16,302,000-13,220,000-28,945,000-14,555,000-12,367,000-14,672,000-20,368,000-16,551,000-2,334,000-16,530,000-12,636,000-18,412,000-20,472,000-14,726,000-13,944,000-15,038,000
Net Income Margin48.0%-0.24-0.45-0.66-1.14-1.48-1.46-1.33-1.39-1.32-1.53-1.12-1.22---------
Free Cashflow71.4%-2,498,000-8,733,0008,814,0008,420,0002,592,000-7,239,000-14,586,000-8,594,000-9,148,000-1,950,000-14,200,000-13,748,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets4.3%59.0057.0061.0057.0052.0056.0057.0062.0065.0067.0062.0063.0050.0064.0064.0078.0049.0050.0068.0087.0090.00
  Current Assets6.7%42.0040.0044.0040.0038.0044.0043.0047.0050.0051.0044.0045.0032.0044.0051.0068.0038.0039.0056.0074.0077.00
    Cash Equivalents11.1%25.0022.0027.0027.0019.0018.0015.0028.0031.0034.0027.0032.0017.0025.0036.0049.0021.0022.0040.0061.0064.00
  Inventory19.0%7.006.007.006.007.005.005.004.003.003.003.002.003.003.003.003.004.005.005.005.004.00
  Net PPE-1.1%5.005.004.004.004.005.004.005.005.006.006.007.008.008.009.0010.0010.0011.0012.0012.0012.00
Liabilities-0.8%16216417117616015315014412612111411187.0085.0085.0085.0083.0075.0074.0077.0067.00
  Current Liabilities-37.8%24.0039.0040.0040.0037.0030.0024.0022.0025.0023.0020.0021.0018.0015.0015.0019.0020.0025.0030.0033.0021.00
Shareholder's Equity2.8%20820219419319119017717516715914913812912812612483.0075.0073.0010.0023.00
  Retained Earnings-0.7%-310-308-303-311-298-286-270-256-227-213-200-186-165-149-147-130-117-99.43-78.95-61.38-47.43
  Additional Paid-In Capital2.8%20820219419319119017717516715914913812912812612483.0075.0073.0071.0071.00
Shares Outstanding8.3%67.0062.0056.0055.0047.0043.0041.0041.0039.0037.0036.0035.00---------
Float------28.00---111---102---101---
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations70.3%-2,347-7,9078,8168,4462,809-6,562-14,482-8,061-9,065-1,756-14,097-13,512-8,313-9,997-13,637-10,575-14,789-17,166-17,680-2,812-11,475
  Share Based Compensation22.7%7746313447145352,2199131,6911,9001,7211,5071,5291,4271,7651,8601,8721,8691,8101,5201,3991,236
Cashflow From Investing81.7%-151-826-2.00-26.00-1,717-677-104-533-83.00-194-103-236-38.00-112-131-86.00-91.00-110-376-490-448
Cashflow From Financing16.1%4,9794,287-9,205204-13810,1981,2985,4546,0788,6869,89128,491-7.0010.00-37.0039,07313,629-493-2,609-81.0065,267

AQST Income Statement

2023-09-30
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($)
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Income Statement [Abstract]    
Revenues$ 13,002,000$ 11,463,000$ 37,377,000$ 36,998,000
Costs and expenses:    
Manufacture and supply4,798,0004,625,00016,152,00014,081,000
Research and development3,196,0003,232,00010,216,00013,203,000
Selling, general and administrative7,385,00012,459,00022,200,00041,067,000
Total costs and expenses15,379,00020,316,00048,568,00068,351,000
Loss from operations(2,377,000)(8,853,000)(11,191,000)(31,353,000)
Other income/ (expenses):    
Interest expense(1,256,000)(1,649,000)(4,064,000)(4,902,000)
Interest expense related to the sale of future revenue, net(56,000)(2,039,000)(163,000)(5,837,000)
Interest and other income (expense), net1,514,0005,00016,156,00034,000
Loss on extinguishment of debt00(353,000)0
Net income (loss) before income taxes(2,175,000)(12,536,000)385,000(42,058,000)
Income taxes(140,000)0144,0000
Net income (loss)(2,035,000)(12,536,000)241,000(42,058,000)
Comprehensive income (loss)$ (2,035,000)$ (12,536,000)$ 241,000$ (42,058,000)
Earnings (loss) per share attributable to common stockholders:    
Basic (in dollars per share)$ (0.03)$ (0.23)$ 0$ (0.90)
Diluted (in dollars per share)$ (0.03)$ (0.23)$ 0$ (0.90)
Weighted average common shares outstanding:    
Basic (in shares)64,678,76153,424,92259,252,76846,828,218
Diluted (in shares)64,678,76153,424,92261,513,73646,828,218

AQST Balance Sheet

2023-09-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 24,917$ 27,273
Trade and other receivables, net8,5504,704
Inventories, net7,0795,780
Prepaid expenses and other current assets1,9112,131
Total current assets42,45739,888
Property and equipment, net4,5514,085
Right-of-use assets, net5,6695,211
Intangible assets, net1,3171,435
Other non-current assets5,4546,451
Total assets59,44857,070
Current liabilities:  
Accounts payable9,9949,946
Accrued expenses5,4687,967
Lease liabilities, current367255
Deferred revenue, current2,6371,513
Liability related to the sale of future revenue, current9851,147
Loans payable, current4,60618,700
Total current liabilities24,05739,528
Loans payable, net34,55533,448
Liability related to the sale of future revenue, net63,51164,112
Lease liabilities5,5095,085
Deferred revenue32,73231,417
Other non-current liabilities2,0112,034
Total liabilities162,375175,624
Contingencies (Note 19)
Stockholders’ deficit:  
Common stock, $0.001 par value. Authorized 250,000,000 shares; 66,740,765 and 54,827,734 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively6755
Additional paid-in capital207,972192,598
Accumulated deficit(310,966)(311,207)
Total stockholders’ deficit(102,927)(118,554)
Total liabilities and stockholders’ deficit$ 59,448$ 57,070
Common stock, shares outstanding (in shares)66,740,76554,827,734
Common stock, shares issued (in shares)66,740,76554,827,734
AQST
Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and AQST-109, an orally delivered epinephrine product candidate for the emergency treatment of allergic reactions, including anaphylaxis. Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey.
 CEO
 WEBSITEwww.aquestive.com
 EMPLOYEES130

Aquestive Therapeutics Inc Frequently Asked Questions


What is the ticker symbol for Aquestive Therapeutics Inc? What does AQST stand for in stocks?

AQST is the stock ticker symbol of Aquestive Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Aquestive Therapeutics Inc (AQST)?

As of Tue Feb 20 2024, market cap of Aquestive Therapeutics Inc is 176.93 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AQST stock?

You can check AQST's fair value in chart for subscribers.

What is the fair value of AQST stock?

You can check AQST's fair value in chart for subscribers. The fair value of Aquestive Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Aquestive Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AQST so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Aquestive Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether AQST is over valued or under valued. Whether Aquestive Therapeutics Inc is cheap or expensive depends on the assumptions which impact Aquestive Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AQST.

What is Aquestive Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Feb 20 2024, AQST's PE ratio (Price to Earnings) is -14.61 and Price to Sales (PS) ratio is 3.44. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AQST PE ratio will change depending on the future growth rate expectations of investors.